GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BSF Enterprise PLC (LSE:BSFA) » Definitions » ROCE %

BSF Enterprise (LSE:BSFA) ROCE % : -51.27% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BSF Enterprise ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BSF Enterprise's annualized ROCE % for the quarter that ended in Sep. 2024 was -51.27%.


BSF Enterprise ROCE % Historical Data

The historical data trend for BSF Enterprise's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BSF Enterprise ROCE % Chart

BSF Enterprise Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROCE %
Get a 7-Day Free Trial -20.00 -14.74 -45.03 -36.05 -43.89

BSF Enterprise Semi-Annual Data
Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.48 -27.02 -34.53 -38.23 -51.27

BSF Enterprise ROCE % Calculation

BSF Enterprise's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2024 )  (A: Sep. 2023 )(A: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2024 )  (A: Sep. 2023 )(A: Sep. 2024 )
=-1.791/( ( (5.261 - 0.304) + (3.495 - 0.29) )/ 2 )
=-1.791/( (4.957+3.205)/ 2 )
=-1.791/4.081
=-43.89 %

BSF Enterprise's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=-1.86/( ( (4.301 - 0.25) + (3.495 - 0.29) )/ 2 )
=-1.86/( ( 4.051 + 3.205 )/ 2 )
=-1.86/3.628
=-51.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BSF Enterprise  (LSE:BSFA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


BSF Enterprise ROCE % Related Terms

Thank you for viewing the detailed overview of BSF Enterprise's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BSF Enterprise Business Description

Traded in Other Exchanges
Address
2 Portman Street, London, GBR, W1H 6DU
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.

BSF Enterprise Headlines

No Headlines